INTRODUCTION

Biperiden HCl

Biperiden HCl is a muscarinic antagonist that has effects

in both the central and peripheral nervous systems. It has
been used in the treatment of arteriosclerotic, idiopathic,
and postencephalitic parkinsonism. It has also been used
to alleviate extrapyramidal symptoms induced by
phenothiazine derivatives and reserpine.

Compound Details:-
 Molecular Formula:- C21H30ClNO
 IUPAC Name:- 1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-
phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride
 Molecular Weight:- 347.9
 Melting Point : >240° C
 Water Solubility:- 0.00426 mg/mL
Mechanism of Action:-Parkinsonism is thought to result
from an imbalance between the excitatory (cholinergic)
and inhibitory (dopaminergic) systems in the corpus
striatum. The mechanism of action of centrally active
anticholinergic drugs such as Biperiden HCl is considered
to relate to competitive antagonism of acetylcholine at
cholinergic receptors in the corpus striatum, which then
restores the balance.

USES:- Biperiden is used to treat the stiffness, tremors,

spasms, and poor muscle control of Parkinson's disease. It
is also used to treat and prevent these same muscular
conditions when they are caused by drugs such as
chlorpromazine (Thorazine), fluphenazine (Prolixin),
perphenazine (Trilafon), and others.

Side Effects:- Nervous system:-Nervous system side

effects have included drowsiness, choreic movements,
reduced rapid eye movement sleep, and anticholinergic
syndrome.
Gastrointestinal:-Gastrointestinal side effects have
included dry mouth, constipation, gastric irritation,
nausea, vomiting, and increased salivation.
Psychiatric:-Psychiatric side effects have included
euphoria, disorientation, agitation, disturbed behavior,
and concentration difficulties.
Hypersensitivity:-Hypersensitivity side effects have
included allergic skin reactions.
 SUMMARY/REPORT

Biperiden, sold under the brand name Akineton among

others, is a medication used to treat Parkinson disease and
certain drug-induced movement disorders. Biperiden is a
weak peripheral anticholinergic agent. It is taken by
mouth, injection into a vein, or muscle. Biperiden is used
for the adjunctive treatment of all forms of Parkinson's
disease (postencephalitic, idiopathic, and arteriosclerotic
Parkinson's) and for reduced sweating in methadone
users. It seems to exert better effects in the
postencephalitic and idiopathic than in the arteriosclerotic
type. Biperiden is also commonly used to improve acute
extrapyramidal side effects related to antipsychotic drug
therapy, such as akathisia. Biperiden HCl is used alone or
together with other medicines (e.g., levodopa) to treat
Parkinson's disease. By improving muscle control and
reducing stiffness, this medicine allows more normal
movements of the body as the disease symptoms are
reduced. Biperiden Hcl is also used to control severe
muscle reactions and other side effects from certain
medicines that are used to treat severe nausea or nervous,
mental, or emotional conditions. Isolated instances of
mental confusion, euphoria, agitation and disturbed
behavior have been reported in susceptible patients. Also,
the central anticholinergic syndrome can occur as an
adverse reaction to properly prescribed anticholinergic
medication, although it is more frequently due to
overdosage. It may also result from concomitant
administration of an anticholinergic agent and a drug that
has secondary anticholinergic actions.
REFERENCE

1. Kar Ashutosh, Medicinal Chemistry, New Age

International Publishers, 8th edition, Page No:-
781
2. V. Alagarsamy, Textbook of Medicinal
Chemistri, Vol 1,Elsevier Publishers, 2010, Page
No:- 326
3. Razadan Balkishen, Medicinal Chemistry, CBS
Publishers and Distributors Pvt. Ltd., 2nd
Edition, page No:- 556-557
4. Larrey D, Ripault M.P., Hepatotoxicity of
psychotropic drugs and drugs of abuse. In,
Kaplowitz N, DeLeve L.D., eds. Drug-induced
liver disease. 3rd ed. Amsterdam: Elsevier Inc,
2013, pp. 443-462.
5. Knollman B.C, eds. Goodman & Gilman’s the
pharmacological basis of therapeutics. 12th ed.
New York: McGraw-Hill, 2011, pp. 609-628.